Addition Therapeutics: One genomic safe site, many DNA insertions

Addition emerged from stealth today as the newest entrant in a small group of companies developing gene-writing therapeutics, differentiated by its retrotransposon technology that naturally integrates sequences into one particular location in the genome, eliminating the need for a gene-targeting module in its medicines.

Addition Therapeutics Inc. CSO Francine Gregoire — a veteran of Moderna Inc. (NASDAQ:MRNA), CRISPR Therapeutics AG (NASDAQ:CRSP) and Beam Therapeutics Inc. (NASDAQ:BEAM) — said she joined Addition because she “was sold” on the potential applications of Addition’s technology. “I saw it as really the next-gen reagent that would address pretty much everything that the other technologies couldn’t do.”...